Gary Schieven

Gary joined the GBG team in 2020. As Director of Clinical Development, he leads clinical development efforts for GBG’s STING agonist or treatment of cancer. As Managing Director of Immunoveda, provides leadership, oversight, and coordination for the development and management of drug discovery efforts for immuno-oncology and for the treatment of immune-related disorders.

Gary brought over 30 years of experience in the Immunology & Oncology Research industry to the GBG Team. He previously held a position with Bristol-Myers Squibb, as an award-winning Senior Research Fellow.

Gary is the author of 112 publications, 12 patents and patent applications, and 41 presentations at scientific meetings. He led drug discovery programs leading to one marketed drug, Sprycel, plus 7 compounds into clinical development, including BMS-986256 currently in Phase II trials for lupus, and BMS-986301 currently in Phase I trials in immuno-oncology.

Gary received his BS in Chemistry from St. John Fisher College in Rochester, NY. He earned a Ph.D. in Biochemistry from the University of California at Berkeley in Berkeley, CA.